C. Ortega

Targeted Nanotherapeutics Encapsulating Liver X Receptor Agonist GW3965 Enhance Antiatherogenic Effects without Adverse Effects on Hepatic Lipid Metabolism in Ldlr−/− Mice

O. Farokhzad, E. Fisher, M. Mahmoudi, 2017, Advanced healthcare materials.

Pathways of smooth muscle foam cell formation in atherosclerosis

G. Francis, Joshua A. Dubland, C. Ortega, 2019, Current opinion in lipidology.

Smooth Muscle Cell-Proteoglycan-Lipoprotein Interactions as Drivers of Atherosclerosis.

S. Allahverdian, G. Francis, C. Ortega, 2020, Handbook of experimental pharmacology.

Low LAL (Lysosomal Acid Lipase) Expression by Smooth Muscle Cells Relative to Macrophages as a Mechanism for Arterial Foam Cell Formation

S. Allahverdian, G. Francis, Ying Wang, 2021, Arteriosclerosis, thrombosis, and vascular biology.

Nanoparticles targeting extra domain B of fibronectin-specific to the atherosclerotic lesion types III, IV, and V-enhance plaque detection and cargo delivery

P. Libby, O. Farokhzad, F. Schoen, 2018, Theranostics.

Targeted Nanotherapeutics Encapsulating Liver X Receptor Agonist GW3965 Enhance Antiatherogenic Effects without Adverse Effects on Hepatic Lipid Metabolism in Ldlr−/− Mice

O. Farokhzad, E. Fisher, M. Mahmoudi, 2017, Advanced healthcare materials.